Authors: Lengfelder, E Reichert, A Schoch, C Haase, D Haferlach, T Loffler, H Staib, P Heyll, A Seifarth, W Saussele, S Fonatsch, C Gassmann, W Ludwig, WD Hochhaus, A Beelen, D Aul, C Sauerland, MC Heinecke, A Hehlmann, R Wormann, B Hiddemann, W Buchner, T

Citation: E. Lengfelder et al., Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia, LEUKEMIA, 14(8), 2000, pp. 1362-1370

Authors: Hochhaus, A Weisser, A La Rosee, P Emig, M Muller, MC Saussele, S Reiter, A Kuhn, C Berger, U Hehlmann, R Cross, NCP

Citation: A. Hochhaus et al., Detection and quantification of residual disease in chronic myelogenous leukemia, LEUKEMIA, 14(6), 2000, pp. 998-1005

Authors: Saussele, S Weisser, A Muller, MC Emig, M La Rosee, P Paschka, P Kuhn, C Willer, A Hehlmann, R Hochhaus, A

Citation: S. Saussele et al., Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes, LEUKEMIA, 14(11), 2000, pp. 2006-2010

Authors: Hochhaus, A Reiter, A Saussele, S Reichert, A Emig, M Kaeda, J Schultheis, B Berger, U Shepherd, PCA Allan, NC Hehlmann, R Goldman, JM Cross, NCP

Citation: A. Hochhaus et al., Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission, BLOOD, 95(1), 2000, pp. 62-66

Authors: Emig, M Saussele, S Wittor, H Weisser, A Reiter, A Willer, A Berger, U Hehlmann, R Cross, NCP Hochhaus, A

Citation: M. Emig et al., Accurate and rapid analysis of residual disease in patients with CML usingspecific fluorescent hybridization probes for real time quantitative RT-PCR, LEUKEMIA, 13(11), 1999, pp. 1825-1832